Desert Control Valuation
Is 8KT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8KT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8KT (€0.49) is trading above our estimate of fair value (€0.18)
Significantly Below Fair Value: 8KT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8KT?
Key metric: As 8KT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 8KT's PB Ratio? | |
|---|---|
| PB Ratio | 3.6x |
| Book | NOK 86.32m |
| Market Cap | NOK 311.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 121.1x |
| Enterprise Value/EBITDA | -4.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 8KT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
IBU IBU-tec advanced materials | 0.6x | 109.4% | €33.3m |
SDF K+S | 0.3x | 61.1% | €2.0b |
DLX Delignit | 0.7x | 27.0% | €24.6m |
BNN BRAIN Biotech | 4.2x | 71.5% | €68.8m |
8KT Desert Control | 3.6x | 42.7% | €311.0m |
Price-To-Book vs Peers: 8KT is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (1.5x).
Price to Book Ratio vs Industry
How does 8KT's PB Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Book vs Industry: 8KT is expensive based on its Price-To-Book Ratio (3.6x) compared to the European Chemicals industry average (1.4x).
Price to Book Ratio vs Fair Ratio
What is 8KT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 8KT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.91
7D
4.9%
1Y
-15.5%
Tokuyama
JP¥196.7b
Produces and sells various chemical products in Japan.
TBT
JP¥16.60
7D
5.7%
1Y
14.5%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-4.4%
1Y
-19.9%